111 results
8-K
EX-99.1
PULM
Pulmatrix, Inc.
13 Aug 24
Pulmatrix Announces Second Quarter 2024 Financial Results and Provides Corporate Update
9:05am
with Cipla as compared to the corresponding period in the previous year.
Research and development expenses decreased approximately $1.3 million to $2.8 …
(in thousands, except share and per share data)
(unaudited)
Three Months Ended
June 30,
Six Months Ended
June 30,
Revenues
Operating expenses:
Research
8-K
EX-99.1
PULM
Pulmatrix, Inc.
10 May 24
Pulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate Update
9:05am
at the beginning of the period.
Research and development expenses decreased approximately $0.4 million to $3.5 million for the three months ended March 31, 2024 … )
Three Months Ended
March 31,
Revenues
Operating expenses
Research and development
General and administrative
Total operating expenses
Income (loss
8-K
EX-99.1
prvxi1p ovy
28 Mar 24
Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update
9:05am
8-K
EX-99.1
wdkeoif0tzxoxng43 sr
9 Nov 23
Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update
9:05am
8-K
EX-99.1
lmzmh9iw
10 Aug 23
Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update
9:05am
8-K
EX-99.1
bltyi
12 May 23
Pulmatrix Announces First Quarter 2023 Financial Results and Provides Corporate Update
9:05am
8-K
EX-99.1
ytxe9i2n
30 Mar 23
Pulmatrix Announces Year-End and Q4 Financial 2022 Results and Provides Corporate Update
9:05am
8-K
EX-99.1
el5d7ll
14 Nov 22
Pulmatrix Announces Third Quarter 2022 Financial Results and Provides Corporate Update
6:17am
8-K
EX-99.1
uwuw0w pkdtde6d
10 Aug 22
Pulmatrix Announces Second Quarter 2022 Financial Results and Provides Corporate Update
9:15am